Sangamo Therapeutics Inc. (SGMO)’s Financial Results Comparing With Intec Pharma Ltd. (NASDAQ:NTEC)

This is therefore a contrasting of the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation in Sangamo Therapeutics Inc. (NASDAQ:SGMO) and Intec Pharma Ltd. (NASDAQ:NTEC). The two are both Biotechnology companies that compete with one another.

Valuation Earnings

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Sangamo Therapeutics Inc. and Intec Pharma Ltd.

Profitability

Table 2 represents Sangamo Therapeutics Inc. (NASDAQ:SGMO) and Intec Pharma Ltd. (NASDAQ:NTEC)’s net margins, return on assets and return on equity.

Analyst Ratings

In next table is shown Sangamo Therapeutics Inc. and Intec Pharma Ltd.’s ratings and recommendations.

Sangamo Therapeutics Inc.’s upside potential is 7.18% at a $10 consensus target price.

Insider and Institutional Ownership

Sangamo Therapeutics Inc. and Intec Pharma Ltd. has shares owned by institutional investors as follows: 57.3% and 40.23%.

... read more at: https://stocksbeat.com/2019/06/12/trending-stock-news/sangamo-therapeutics-inc-sgmos-financial-results-comparing-with-intec-pharma-ltd-nasdaqntec/

Leave a Reply